Evidence map›Paper›PMID 30050310›Full record

ArticleOncoTargets and therapy2018

Promoter methylation analysis of

Bayram Bayramov, Sezgin Gunes, Recep Buyukalpelli, Oğuz Aydın, Ralf Henkel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Bayram BayramovMedical Biology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey, sgunes@omu.edu.tr.
Sezgin GunesMedical Biology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey, sgunes@omu.edu.tr.
Recep BuyukalpelliMultidisciplinary Molecular Medicine, Health Sciences Institute, Ondokuz Mayis University, Samsun, Turkey, sgunes@omu.edu.tr.
Oğuz AydınPathology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Ralf HenkelDepartment of Medical Bioscience, University of the Western Cape, Bellville, South Africa.
Ondokuz Mayıs University · TRUniversity of the Western Cape · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimUrothelial bladder cancer arises from the accumulation of multiple epigenetic and genetic changes. We aimed to investigate the specificity and sensitivity of gene-specific promoter methylation of PATIENTS AND

methodsIn the current study, 65 patients with urothelial bladder cancer and 35 controls without any history of cancer were recruited. Methylation profiles of

resultsMethylation of

conclusionAberrant promoter methylation of

Indexed as

biomarkerCDH1p14ARFurineurine cytologyurothelial bladder cancer

Identifiers

PMID30050310
PMCPMC6056157
OpenAlexW2884000940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.